Screener
Supernus Pharmaceuticals SUPN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share | ||
| Basic | $(0.04) | $(0.21) |
| Diluted | $(0.04) | $(0.21) |
| Weighted average shares outstanding | ||
| Basic | 57,647,548 | 55,864,692 |
| Diluted | 57,647,548 | 55,864,692 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's EPS (diluted)?
- Supernus Pharmaceuticals (SUPN) reported EPS (diluted) of -$0.04 in Q1 2026.
- How has Supernus Pharmaceuticals's EPS (diluted) changed year-over-year?
- Supernus Pharmaceuticals's EPS (diluted) increased by 81.0% year-over-year, from -$0.21 to -$0.04.
- What is the long-term trend for Supernus Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's EPS (diluted) has grown at a -8.7% compound annual growth rate (CAGR), from $0.98 to -$0.68.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Supernus Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude